The ability of PEDF to attenuate metastatic markers such as matrix 1 metalloproteinase (MT1-MMP) and focal adhesion kinase (FAK) has been shown in our lab in various types of cancers, including chondrosarcoma [14], breast and prostate cancer [15]. This evidence concerns the gene SERPINF1 and Familial prostate cancer.